Related Experiment Video
Updated: Jul 5, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
[Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line]
1Centro de Altos Estudios en Ciencias de la Salud (CAECIS), Universidad Abierta Interamericana (UAI), Buenos Aires, Argentina. alicia.fuchs@vaneduc.edu.ar
Abstract:
Lonidamine (1-[2,4-dichlorophenyl methyl]-1H indazole-3-carboxylic acid), Ind, is an antitumoral drug acting on mitochondria and glucose metabolism. Cell growth and metabolic effects of Ind and drug post-treatment effect were investigated in undifferentiated HT-29 human colonic carcinoma cell line which requires high glucose medium concentration for growth. 0.2 mM Ind significantly decreased cell spreading and growth in monolayer or agar cell culture. After drug treatment cell growth was reestablished to control value within 24 h. Ind modified glycoconjugates and mannose-receptor distribution (analyzed by confocal microscopy), while glucose-glycogen and protein synthesis were not affected, these being the possible reasons for the fast reversible effect.

